Saurabh Saha

Last updated
Saurabh Saha
NationalityAmerican
EducationBSc, MSc, MD, and PhD
Alma mater California Institute of Technology
Johns Hopkins University
Harvard University
University of Oxford
OccupationCancer drug discovery
Known forTranslational medicine
Cancer biosurgery

Saurabh Saha is an American physician, scientist, cancer researcher, and biotech entrepreneur. [1]

Contents

Education

Saha received his undergraduate degree in biology from the California Institute of Technology. [2] He also attended both Harvard Business School and Oxford University. [3] Saha trained under Bert Vogelstein during his studies at the Johns Hopkins School of Medicine, [4] where he received both an MD and a PhD in cancer genetics. [5]

Career

After leaving academia, Saha joined the management consulting firm McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City. [6] In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts. [5] Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries [7] [3] Saha serves as a venture partner for the life sciences venture capital firm, Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic. [8]

In 2016, Saha was appointed as President and CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as lupus, inflammatory bowel disease, rheumatoid arthritis and others. [9] [10] [11]

Saha has published in periodicals including the Nature and Science journals, where he has reported translational research and development discoveries in cancer research. [12] [13] [14] [15] [16] [17] [18] He is also on the editorial boards of the American Journal of Clinical Oncology, [19] Journal of Translational Medicine, [20] and Cancer Biology & Therapy. [21]

Related Research Articles

Adenocarcinoma Medical condition

Adenocarcinoma (AC) is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both. Adenocarcinomas are part of the larger grouping of carcinomas, but are also sometimes called by more precise terms omitting the word, where these exist. Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name—however, esophageal adenocarcinoma does to distinguish it from the other common type of esophageal cancer, esophageal squamous cell carcinoma. Several of the most common forms of cancer are adenocarcinomas, and the various sorts of adenocarcinoma vary greatly in all their aspects, so that few useful generalizations can be made about them.

Bert Vogelstein American oncologist (born 1949)

Bert Vogelstein is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center. A pioneer in the field of cancer genomics, his studies on colorectal cancers revealed that they result from the sequential accumulation of mutations in oncogenes and tumor suppressor genes. These studies now form the paradigm for modern cancer research and provided the basis for the notion of the somatic evolution of cancer.

P110α Human protein-coding gene

The phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, also called p110α protein, is a class I PI 3-kinase catalytic subunit. The human p110α protein is encoded by the PIK3CA gene.

KRAS

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

Victor Velculescu

Victor E. Velculescu is a Professor of Oncology and Co-Director of Cancer Biology at The Johns Hopkins University School of Medicine. He is internationally known for his discoveries in genomics and cancer research.

PTP4A3

Protein tyrosine phosphatase type IVA 3 is an enzyme that in humans is encoded by the PTP4A3 gene.

MCC (gene)

Colorectal mutant cancer protein is a protein that in humans is encoded by the MCC gene.

PLXDC1

Plexin domain-containing protein 1 is a protein that in humans is encoded by the PLXDC1 gene.

Clostridium novyi (oedematiens) a Gram-positive, endospore- forming, obligate anaerobic bacteria of the class Clostridia. It is ubiquitous, being found in the soil and faeces. It is pathogenic, causing a wide variety of diseases in man and animals. It comes in three types, labelled A, B, and a non-pathogenic type C distinguished by the range of toxins they produce. Some authors include Clostridium haemolyticum as Clostridium novyi type D. C novyi is closely related to Clostridium botulinum types C and D as Yoshimasa Sasaki et al. have demonstrated by 16S rDNA sequence analysis.

Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells. It is a biochemical laboratory method for the characterization and identification of the DNA or RNA sequences of cancer cell(s).

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously Deputy Director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

Isogenic human disease models are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro. They are provided with a genetically matched 'normal cell' to provide an isogenic system to research disease biology and novel therapeutic agents. They can be used to model any disease with a genetic foundation. Cancer is one such disease for which isogenic human disease models have been widely used.

Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies.

STAG3 (gene)

Stromal antigen 3 is a protein that in humans is encoded by the STAG3 gene. STAG3 protein is a component of a cohesin complex that regulates the separation of sister chromatids specifically during meiosis. STAG3 appears to participate in sister-chromatid cohesion throughout the meiotic process in human oocytes.

Circulating tumor DNA

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. ctDNA should not be confused with cell-free DNA (cfDNA), a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin. Because ctDNA may reflect the entire tumor genome, it has gained traction for its potential clinical utility; “liquid biopsies” in the form of blood draws may be taken at various time points to monitor tumor progression throughout the treatment regimen.

The American Association for Cancer Research gives several annual awards for significant contributions to the field of cancer research.

Clostridium novyi-NT is a modified form of Clostridium novyi that is under investigation as a cancer treatment. It is one of several pathogenic species of Clostridium bacteria that have been examined for that purpose. The modification eliminated the secretion of α-toxin.

Kenneth Wayne Kinzler is a professor of oncology, and director of the Ludwig Center at Johns Hopkins University at the Sidney Kimmel Comprehensive Cancer Center.

BEAMing, which stands for beads, emulsion, amplification, magnetics, is a highly sensitive digital PCR method that combines emulsion PCR and flow cytometry to identify and quantify specific somatic mutations present in DNA.

Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.

References

  1. ↑ "Executive Profile". Bloomberg.
  2. ↑ "Commencement" (PDF). Retrieved September 19, 2014.
  3. 1 2 "Saurabh Saha" . Retrieved September 15, 2014.
  4. ↑ Alice Park (August 13, 2014). "Treating Cancer With Bacteria Shows Real Promise". Time Magazine . Retrieved September 15, 2015.
  5. 1 2 "Saurabh Saha" . Retrieved September 15, 2014.
  6. ↑ "Biomed Valley Discoveries" . Retrieved September 19, 2014.
  7. ↑ Mitch Leslie (August 13, 2014). "Bacteria shrink tumors in humans, dogs". Science Magazine. Retrieved September 15, 2014.
  8. ↑ Fidler, Ben (September 14, 2016). "Sofinnova, Atlas Put $35M Into Delinia to Tackle Autoimmune Diseases". Xconomy.
  9. ↑ Carroll, John (September 14, 2016). "Atlas Partner Saha Takes the Helm at Delinia, Looking to Disrupt Autoimmune R&D". Endpoints News.
  10. ↑ Adams, Ben (January 26, 2017). "Celgene Splashes Out $300M on Delinia Autoimmune Biotech Buy". FierceBiotech.
  11. ↑ Gormley, Brian (January 26, 2017). "Celgene to Pay Up to $775 Million to Buy Biotech Startup Delinia". The Wall Street Journal.
  12. ↑ Saha S; Sparks AB; Rago C; Akmaev V; Wang CJ; Vogelstein B; Kinzler KW; Velculescu VE (May 2002). "Using the transcriptome to annotate the genome". Nature Biotechnology. 20 (5): 508–12. doi:10.1038/nbt0502-508. PMID   11981567. S2CID   12709815.
  13. ↑ Christoph Lengauer; Luis A. Diaz, Jr & Saurabh Saha (May 2005). "Outlook: Cancer drug discovery through collaboration". Nature Reviews Drug Discovery. 4 (5): 375–380. doi:10.1038/nrd1722. PMID   15864266. S2CID   1720653.
  14. ↑ Saurabh Saha; et al. (October 11, 2001). "A Phosphatase Associated with Metastasis of Colorectal Cancer". Science. Retrieved September 15, 2014.
  15. ↑ "Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers". Science. May 2003.
  16. ↑ "Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses". Science Translational Medicine. Aug 2014.
  17. ↑ Bardelli, Alberto; Parsons, D. Williams; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Saha, Saurabh; Markowitz, Sanford; Willson, James K. V.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E. (9 May 2003). "Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers". Science. 300 (5621): 949. doi:10.1126/science.1082596. PMID   12738854. S2CID   85934154.
  18. ↑ Roberts, Nicholas J.; Zhang, Linping; Janku, Filip; Collins, Amanda; Bai, Ren-Yuan; Staedtke, Verena; Rusk, Anthony W.; Tung, David; Miller, Maria; Roix, Jeffrey; Khanna, Kristen V.; Murthy, Ravi; Benjamin, Robert S.; Helgason, Thorunn; Szvalb, Ariel D.; Bird, Justin E.; Roy-Chowdhuri, Sinchita; Zhang, Halle H.; Qiao, Yuan; Karim, Baktiar; McDaniel, Jennifer; Elpiner, Amanda; Sahora, Alexandra; Lachowicz, Joshua; Phillips, Brenda; Turner, Avenelle; Klein, Mary K.; Post, Gerald; Diaz, Luis A.; Riggins, Gregory J.; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Bettegowda, Chetan; Huso, David L.; Varterasian, Mary; Saha, Saurabh; Zhou, Shibin (13 August 2014). "Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses". Science Translational Medicine. 6 (249): 249ra111. doi:10.1126/scitranslmed.3008982. PMC   4399712 . PMID   25122639.
  19. ↑ "Editorial board" . Retrieved September 15, 2014.
  20. ↑ "Editorial board" . Retrieved September 15, 2014.
  21. ↑ "Editorial board" . Retrieved September 15, 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.